Labiotech.eu - Europe's leading Biotech News Website

Latest Posts

Paris Meetup Deinove header 2

Interview 10 Oct 2018

How to Make Industrial Biotech Pay

Making enough money to survive long enough to get a product to market can be tough for any biotech, but even more so for companies operating in the industrial space, where it can be less easy to predict development time and potential financial returns. At our recent Refresh event in Paris, Emmanuel Petiot, CEO of […]

October 10, 2018 - 5 minutesmins - By Helen Albert

Slow release drug injection

News and Trends 9 Oct 2018

Slow-Release Drug Biotech IPO Raises €30M

The French biotech MedinCell, an injectable slow-release drug specialist, has received a shot of success as its IPO raises €30M in the Euronext stock exchange in Paris. MedinCell is hoping to improve patient compliance with medication regimes by injecting them with a drug-infused gel. Patient compliance with taking medication can be as low as 30% […]

October 9, 2018 - 2 minutesmins - By Jonathan Smith

Cortisol hormone drugs

News and Trends 9 Oct 2018

Hormone Therapy for Inherited Hormonal Disorder Fails at Phase III

A European Phase III trial has become a major stress for British biotech Diurnal. Its specially designed hormone therapy was no better than conventional therapies in treating an inherited hormonal disorder. Congenital adrenal hyperplasia is a rare genetic condition where patients lack crucial enzymes for making hormones. The most common form lacks 21-hydroxylase, the enzyme […]

October 9, 2018 - 3 minutesmins - By Jonathan Smith

Underserved disease feature header

In Depth 9 Oct 2018

How to Capitalize on Opportunities in Underserved Disease Areas

Developing treatments for underserved diseases can be surprisingly profitable for biotechs, we asked the experts to tell us more about how best to exploit these areas. We hear a lot about cancer therapies or drugs to target heart disease in the press, but overall a lot less about treatments for more underserved areas. Often successful […]

October 9, 2018 - 9 minutesmins - By Helen Albert

Cannabinoid drugs GW story Headerb

More News! 8 Oct 2018

Cannabinoid Drugs Company Raises $300M in Public Offering

GW Pharmaceuticals, a British biotech developing cannabinoid drugs, is on a high after a successful $300M public offering on the Nasdaq Stock Market. The company announced the public offering swiftly after its lead cannabinoid drug, Epidiolex, made history by being the first cannabinoid drug to obtain approval from the FDA earlier this year. GW plans […]

October 8, 2018 - 2 minutesmins - By Jonathan Smith

Sitryx immunometabolism cancer inflammation

News and Trends 8 Oct 2018

Oxford Biotech Launches with €26M to Target ‘Immunometabolism’

Sitryx has launched today with the goal of treating cancer and inflammatory conditions by targeting the metabolism of immune cells, a promising area of research. The new company has kicked off with a €26M Series A round co-led by two specialized investors, SV Health and Sofinnova Partners. Sitryx also has investment from GSK, with […]

October 8, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

ADVERTISEMENT

Spanish biotech industry biospain

In Depth 8 Oct 2018

Behind the Scenes of the Spanish Biotech Industry’s Boom

The Spanish biotech industry is booming, but from my conversations with industry players elsewhere in Europe, it seems the country’s biotech industry keeps being a mystery for many. I caught up with experts at the Biospain conference to draw an overview of how biotech in Spain is doing in 2018. When we talk about biotech […]

October 8, 2018 - 5 minutesmins - By Clara Rodríguez Fernández

Antivenom Black Mamba Header Edited

News and Trends 5 Oct 2018

Lab-Grown Antivenom Shows Potential for Curing Black Mamba Snakebite

Antivenoms could one day be made in the lab instead of in animals. Researchers from the Technical University of Denmark have neutralized black mamba venom in mice with lab-grown human antibodies for the first time. Snakebite is a serious problem, causing the deaths of around 100,000 people every year, and about three times that number […]

October 5, 2018 - 3 minutesmins - By Jonathan Smith

Leuven biotech of the week wikimedia Edited

Startup Scout 5 Oct 2018

This Biotech Sticks Bacterial Proteins Together to Fight Antibiotic Resistance

This week’s biotech has its base in Leuven, Belgium. The newly-founded Aelin Therapeutics hopes to combat antibiotic resistance by doing the pharmacological equivalent of boiling an egg. Mission: To develop a new type of drugs to kill bacteria that are resistant to antibiotics. In the future, the drugs could also be used to kill pathogenic […]

October 5, 2018 - 3 minutesmins - By Jonathan Smith

NobelPrizeWinners story Edited

News and Trends 4 Oct 2018

This Year’s Nobel Prizes Highlight Advances in Biotechnology

Immune system brakes, optical tweezers, and enzyme evolution. Three separate subjects that span this year’s Nobel Prizes in Physiology or Medicine, Physics and Chemistry. Despite the differences in theory, however, the diverse discoveries have one thing in common: they have applications in the biotechnology industry, Labiotech’s favorite subject. Releasing the immune system’s brakes in cancer […]

October 4, 2018 - 5 minutesmins - By Jonathan Smith

artificial pancreas blood sugar type 1 diabetes

News and Trends 3 Oct 2018

Algorithm Proves Better Than Humans at Controlling Blood Sugar in Type 1 Diabetes

A clinical trial has shown that letting an algorithm decide the amount of insulin a person with type 1 diabetes needs can help keep blood sugar levels under control. The algorithm, being developed at the University of Cambridge, is able to predict how much insulin is needed at each point in time based on the […]

October 3, 2018 - 3 minutesmins - By Clara Rodríguez Fernández

Inotrem Septic Shock Blood Infection Header

News and Trends 2 Oct 2018

Septic Shock Drug Shows Promise for Personalized Medicine

Septic shock may no longer be as shocking in the future, as a Phase IIa trial brings hope for a personalized immunomodulatory treatment from the French biotech Inotrem. In sepsis, the immune system overreacts to the infection of a pathogen, causing uncontrolled inflammation throughout the body and organ failure. This can lead to septic […]

October 2, 2018 - 2 minutesmins - By Jonathan Smith

ADVERTISEMENT